# Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-guidance-for-industry/716f5680-73b2-4cf4-a88d-c5ade3c8aecd

> FDA guidance document: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry. Issue date: June 14, 2024. Get complete insights and analysis.

---

## Details

- Title: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-06-14
- Comment Close Date: 2022-09-25
- Last Changed: 2024-07-29
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-0235">FDA-2022-D-0235</a>

## Related Documents

- [Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-human-radiolabeled-mass-balance-studies/3a1b0e14-f87e-4c72-b198-baa24f196e9a)
- [Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-drug-interaction-studies-with-combined-oral-contraceptives-guidance-for-industry-guidance-for-industry/66dca3d2-f3c0-447f-8085-fd2e7ebd60c6)
- [Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals](https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-evaluation-of-the-immunotoxic-potential-of-pharmaceuticals/160dff53-faf3-4095-b37e-414e108646cf)